 | Up a level |
Burnett, Alan, Cavenagh, Jamie, Russell, Nigel, Hills, Robert, Kell, Jonathan, Jones, Gail, Nielsen, Ove Juul, Khwaja, Asim, Thomas, Ian, Clark, Richard 
ORCID: 0000-0002-1261-3299 et al (show 1 more authors)
(2016)
Defining The Dose Of Gemtuzumab Ozogamicin In Combination With Induction Chemotherapy In Acute Myeloid Leukemia: A Comparison Of 3 Mg/M2 With 6 Mg/M2 In The NCRI AML17 Trial.
Haematologica: the hematology journal, 101 (6).
pp. 724-731.
Dennis, Mike, Thomas, Ian F, Ariti, Cono, Upton, Laura, Burnett, Alan K, Gilkes, Amanda, Radia, Rohini, Hemmaway, Claire, Mehta, Priyanka, Knapper, Steven et al (show 5 more authors)
(2021)
Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients.
BLOOD ADVANCES, 5 (24).
pp. 5621-5625.
Dennis, Mike, Burnett, Alan, Hills, Robert, Thomas, Ian, Ariti, Cono, Severinsen, Marianne T, Hemmaway, Claire, Greaves, Paul, Clark, Richard E ORCID: 0000-0002-1261-3299, Copland, Mhairi et al (show 1 more authors)
(2021)
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
BRITISH JOURNAL OF HAEMATOLOGY, 194 (2).
pp. 298-308.